University of Michigan Rogel Cancer Center | Strategic Alliance Partners

Connect with us:

Latest from University of Michigan Rogel Cancer Center

Devimistat Plus Gemcitabine/Cisplatin Moves to Phase 2 Setting in Frontline Biliary Tract Cancer

September 03, 2021

Devimistat in combination with gemcitabine and cisplatin has moved into the phase 2 portion of a phase 1b/2 trial studying the regimen as a first-line treatment for patients with locally advanced unresectable or metastatic biliary tract cancer.

Dr. Gadgeel on Updated KEYNOTE-189 Data in NSCLC

June 18, 2019

Shirish M. Gadgeel, MD, MBBS, professor, University of Michigan Medicine, discusses the updated results of the phase III KEYNOTE-189 trial in metastatic nonsquamous non-small cell lung cancer (NSCLC).

Dr. Arenberg on Low-Cost Intervention to Improve Tobacco Cessation for Lung Cancer

April 03, 2017

David Arenberg, MD, associate professor, Department of Internal Medicine at the University of Michigan, discusses preliminary results of a low-cost intervention to improve tobacco cessation practices within a large university health system.